- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
ISRN Obstetrics and Gynecology
Volume 2012 (2012), Article ID 172808, 7 pages
Early Detection of Maternal Risk for Preeclampsia
1Department of Obstetrics and Gynecology, University Hospital Essen, Hufelandstraße 55, 45147 Essen, Germany
2Institute of Molecular Biology, University Hospital, Hufelandstraße 55, 45147 Essen, Germany
3Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London SE5 9RS, UK
Received 8 April 2012; Accepted 19 June 2012
Academic Editors: K. Chan, A. Malek, A. Martin-Hidalgo, and C. Romero
Copyright © 2012 B. Mikat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. Villar, “Eclampsia and pre-eclampsia: a health problem for 2000 years,” in Preeclampsia, H. Critchley, A. MacLean, and L. Poston, Eds., pp. 189–207, RCOG Press, London, UK, 2003.
- M. Noris, N. Perico, and G. Remuzzi, “Mechanisms of disease: pre-eclampsia,” Nature Clinical Practice Nephrology, vol. 1, no. 2, pp. 98–120, 2005.
- D. J. P. Barker, C. Osmond, T. J. Forsen, E. Kajantie, and J. G. Eriksson, “Maternal and social origins of hypertension,” Hypertension, vol. 50, no. 3, pp. 565–571, 2007.
- D. J. P. Barker, “Intrauterine programming of adult disease,” Molecular Medicine Today, vol. 1, no. 9, pp. 418–423, 1995.
- K. M. Godfrey, H. M. Inskip, and M. A. Hanson, “The long-term effects of prenatal development on growth and metabolism,” Seminars in Reproductive Medicine, vol. 29, no. 3, pp. 257–265, 2011.
- J. C. Cross, D. Baczyk, N. Dobric et al., “Genes, development and evolution of the placenta,” Placenta, vol. 24, no. 2-3, pp. 123–130, 2003.
- J. M. Roberts and D. W. Cooper, “Pathogenesis and genetics of pre-eclampsia,” The Lancet, vol. 357, no. 9249, pp. 53–56, 2001.
- C. W. Redman and I. L. Sargent, “Latest advances in understanding preeclampsia,” Science, vol. 308, no. 5728, pp. 1592–1594, 2005.
- V. D. Winn, M. Gormley, and S. J. Fisher, “The impact of preeclampsia on gene expression at the maternal-fetal interface,” Pregnancy Hypertension, vol. 1, no. 1, pp. 100–108, 2011.
- Y. Zhou, C. H. Damsky, K. Chiu, J. M. Roberts, and S. J. Fisher, “Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts,” Journal of Clinical Investigation, vol. 91, no. 3, pp. 950–960, 1993.
- J. P. Kusanovic, R. Romero, T. Chaiworapongsa et al., “A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia Prediction of preeclampsia,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 22, no. 11, pp. 1021–1038, 2009.
- A. Rolfo, A. Many, A. Racano et al., “Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies,” PLoS ONE, vol. 5, no. 10, Article ID e13288, 2010.
- R. E. Banks, M. A. Forbes, J. Searles et al., “Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1,” Molecular Human Reproduction, vol. 4, no. 4, pp. 377–386, 1998.
- M. L. Veronese, A. Mosenkis, K. T. Flaherty et al., “Mechanisms of hypertension associated with BAY 43-9006,” Journal of Clinical Oncology, vol. 24, no. 9, pp. 1363–1369, 2006.
- H. M. W. Verheul and H. M. Pinedo, “Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition,” Nature Reviews Cancer, vol. 7, no. 6, pp. 475–485, 2007.
- S. Verlohren, I. Herraiz, O. Lapaire, et al., “The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients,” American Journal of Obstetrics & Gynecology, vol. 206, no. 1, pp. 58.e1–58.e8, 2012.
- S. Rana, C. E. Powe, S. Salahuddin et al., “Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia,” Circulation, vol. 125, no. 7, pp. 911–919, 2012.
- U. Perni, C. Sison, V. Sharma, et al., “Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy,” Hypertension, vol. 59, no. 3, pp. 740–746, 2012.
- A. Rajakumar, A. S. Cerdeira, S. Rana, et al., “Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia,” Hypertension, vol. 59, no. 2, pp. 256–264, 2012.
- A. Gellhaus, M. Schmidt, C. Dunk, S. J. Lye, R. Kimmig, and E. Winterhager, “Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia,” Molecular Human Reproduction, vol. 12, no. 6, pp. 389–399, 2006.
- A. Gellhaus, M. Schmidt, C. Dunk, S. J. Lye, and E. Winterhager, “The circulating proangiogenic factors CYR61 (CCN1) and NOV (CCN3) are significantly decreased in placentae and sera of preeclamptic patients,” Reproductive Sciences, vol. 14, no. 8, pp. 46–52, 2007.
- N. Wolf, W. Yang, C. E. Dunk et al., “Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1α and transforming-growth factor-β3 in the human trophoblast,” Endocrinology, vol. 151, no. 6, pp. 2835–2845, 2010.
- W. Yang, J. Wagener, and A. Gellhaus, “Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3,” Human Reproduction, vol. 26, no. 10, pp. 2850–2860, 2011.
- T. Plösch, A. Gellhaus, E. M. van Straten et al., “The liver X receptor, (LXR) and its target gene ABCA1 are regulated upon low oxygen in human trophoblast cells: a reason for alterations in preeclampsia?” Placenta, vol. 31, no. 10, pp. 910–918, 2010.
- P. Ugocsai, A. Hohenstatt, G. Paragh et al., “HIF-1β determines ABCA1 expression under hypoxia in human macrophages,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 2, pp. 241–252, 2010.
- E. Bujold, A. M. Morency, S. Roberge, Y. Lacasse, J. C. Forest, and Y. Giguère, “Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis,” Journal of Obstetrics and Gynaecology Canada, vol. 31, no. 9, pp. 818–826, 2009.
- J. C. Gris, C. Chauleur, N. Molinari, et al., “Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomized controlled NOH-PE trial,” Thrombosis and Haemostasis, vol. 106, no. 6, pp. 1053–1061, 2011.
- J. I. de Vries, M. G. van Pampus, W. M. Hague, P. D. Bezemer, J. H. Joosten, and FRUIT investigators, “Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset preeclampsia in women with inheritable thrombophilia: the FRUIT-RCT,” Journal of Thrombosis and Haemostasis, vol. 10, no. 1, pp. 64–72, 2012.
- C. K. H. Yu, G. C. S. Smith, A. T. Papageorghiou, A. M. Cacho, and K. H. Nicolaides, “An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women,” American Journal of Obstetrics and Gynecology, vol. 193, no. 2, pp. 429–436, 2005.
- B. Sibai, G. Dekker, and M. Kupferminc, “Pre-eclampsia,” The Lancet, vol. 365, no. 9461, pp. 785–799, 2005.
- E. A. P. Steegers, P. von Dadelszen, J. J. Duvekot, and R. Pijnenborg, “Pre-eclampsia,” The Lancet, vol. 376, no. 9741, pp. 631–644, 2010.
- C. Benedetto, L. Marozio, A. M. Tavella, L. Salton, S. Grivon, and F. Di Giampaolo, “Coagulation disorders in pregnancy: acquired and inherited thrombophilias,” Annals of the New York Academy of Sciences, vol. 1205, pp. 106–117, 2010.
- R. Skjaerven, A. J. Wilcox, and R. T. Lie, “The interval between pregnancies and the risk of preeclampsia,” The New England Journal of Medicine, vol. 346, no. 1, pp. 33–38, 2002.
- L. C. Y. Poon, I. Staboulidou, N. Maiz, W. Plasencia, and K. H. Nicolaides, “Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11–13 weeks,” Ultrasound in Obstetrics and Gynecology, vol. 34, no. 2, pp. 142–148, 2009.
- L. C. Y. Poon, N. A. Kametas, C. Valencia, T. Chelemen, and K. H. Nicolaides, “Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11–13 weeks,” Hypertension in Pregnancy, vol. 30, no. 1, pp. 93–107, 2011.
- I. A. Brosens, W. B. Robertson, and H. G. Dixon, “The role of spiral arteries in the pathogenesis of preeclampsia,” in Obstetrics and Gynecology Annual, R. M. Wynn, Ed., pp. 177–191, Appleton-Century-Crafts, New York, NY, USA, 1972.
- R. Pijnenborg, L. Vercruysse, and M. Hanssens, “The uterine spiral arteries in human pregnancy: facts and controversies,” Placenta, vol. 27, no. 9-10, pp. 939–958, 2006.
- T. R. Lovgren, L. Dugoff, and H. L. Galan, “Uterine artery Doppler and prediction of preeclampsia,” Clinical Obstetrics and Gynecology, vol. 53, no. 4, pp. 888–898, 2010.
- R. O. Bahado-Singh and C. Jodicke, “Uterine artery Doppler in first-trimester pregnancy screening,” Clinical Obstetrics and Gynecology, vol. 53, no. 4, pp. 879–887, 2010.
- L. Carbillon, “First trimester uterine artery Doppler for the prediction of preeclampsia and foetal growth restriction,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 25, no. 7, pp. 877–883, 2012.
- H. S. Cuckle, “Screening for pre-eclampsia-lessons from aneuploidy screening,” Placenta, vol. 32, supplement 1, pp. S42–S48, 2011.
- F. Costa, P. Murthi, R. Keogh, and N. Woodrow, “Early screening for preeclampsia,” Revista Brasileira de Ginecologia e Obstetrícia, vol. 33, no. 11, pp. 367–375, 2011.
- A. C. Pedrosa and A. Matias, “Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers.,” Journal of Perinatal Medicine, vol. 39, no. 6, pp. 619–635, 2011.
- H. Stepan, A. Geipel, F. Schwarz, T. Krämer, N. Wessel, and R. Faber, “Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion,” American Journal of Obstetrics and Gynecology, vol. 198, no. 2, pp. 175.e1–175.e6, 2008.
- C. J. Lockwood, G. Krikun, R. Caze, M. Rahman, L. F. Buchwalder, and F. Schatz, “Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis,” Annals of the New York Academy of Sciences, vol. 1127, pp. 67–72, 2008.
- M. Schmidt, C. Dogan, C. Birdir et al., “Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 11, pp. 1504–1510, 2007.
- M. Schmidt, C. Dogan, C. Birdir et al., “Placental growth factor: a predictive marker for preeclampsia?” Gynakologisch-geburtshilfliche Rundschau, vol. 49, no. 2, pp. 94–99, 2009.
- R. Akolekar, E. Zaragoza, L. C. Y. Poon, S. Pepes, and K. H. Nicolaides, “Maternal serum placental growth factor at to weeks of gestation in the prediction of pre-eclampsia,” Ultrasound in Obstetrics and Gynecology, vol. 32, no. 6, pp. 732–739, 2008.
- L. J. Vatten, A. Eskild, T. I. L. Nilsen, S. Jeansson, P. A. Jenum, and A. C. Staff, “Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 196, no. 3, pp. 239.e1–239.e6, 2007.
- S. Rana, S. A. Karumanchi, R. J. Levine et al., “Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia,” Hypertension, vol. 50, no. 1, pp. 137–142, 2007.
- S. Kuc, E. J. Wortelboer, B. B. van Rijn, A. Franx, G. H. A. Visser, and P. C. J. I. Schielen, “Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review,” Obstetrical and Gynecological Survey, vol. 66, no. 4, pp. 225–239, 2011.
- B. Mikat, A. Zeller, A. Scherag, et al., “βhCG and PAPP-A in first trimester: predictive factors for preeclampsia?” Hypertens Pregnancy, vol. 31, no. 2, pp. 261–267, 2012.
- K. Spencer, N. J. Cowans, and K. H. Nicolaides, “Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia,” Prenatal Diagnosis, vol. 28, no. 1, pp. 7–10, 2008.
- R. Akolekar, A. Syngelaki, R. Sarquis, M. Zvanca, and K. H. Nicolaides, “Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks,” Prenatal Diagnosis, vol. 31, no. 1, pp. 66–74, 2011.
- R. Akolekar, A. Etchegaray, Y. Zhou, N. Maiz, and K. H. Nicolaides, “Maternal serum activin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy,” Fetal Diagnosis and Therapy, vol. 25, no. 3, pp. 320–327, 2009.
- R. Akolekar, R. Minekawa, A. Veduta, X. C. Romero, and K. H. Nicolaides, “Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy,” Prenatal Diagnosis, vol. 29, no. 8, pp. 753–760, 2009.
- B. Huppertz, M. Sammar, I. Chefetz, P. Neumaier-Wagner, C. Bartz, and H. Meiri, “Longitudinal determination of serum placental protein 13 during development of preeclampsia,” Fetal Diagnosis and Therapy, vol. 24, no. 3, pp. 230–236, 2008.
- A. Khalil, N. J. Cowans, K. Spencer, S. Goichman, H. Meiri, and K. Harrington, “First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk,” Prenatal Diagnosis, vol. 29, no. 8, pp. 781–789, 2009.
- I. Chafetz, I. Kuhnreich, M. Sammar et al., “First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction,” American Journal of Obstetrics and Gynecology, vol. 197, no. 1, pp. 35.e1–37.e1, 2007.
- K. Spencer, N. J. Cowans, I. Chefetz, J. Tal, and H. Meiri, “First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia,” Ultrasound in Obstetrics and Gynecology, vol. 29, no. 2, pp. 128–134, 2007.
- O. Burger, E. Pick, J. Zwickel et al., “Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies,” Placenta, vol. 25, no. 7, pp. 608–622, 2004.
- C. Garlanda, B. Bottazzi, A. Bastone, and A. Mantovani, “Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility,” Annual Review of Immunology, vol. 23, pp. 337–366, 2005.
- L. C. Y. Poon, R. Akolekar, R. Lachmann, J. Beta, and K. H. Nicolaides, “Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks,” Ultrasound in Obstetrics and Gynecology, vol. 35, no. 6, pp. 662–670, 2010.
- L. C. Y. Poon, V. Stratieva, S. Piras, S. Piri, and K. H. Nicolaides, “Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks,” Prenatal Diagnosis, vol. 30, no. 3, pp. 216–223, 2010.
- J. P. Granger, B. T. Alexander, M. T. Llinas, W. A. Bennett, and R. A. Khalil, “Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction,” Hypertension, vol. 38, no. 3, pp. 718–722, 2001.
- S. Sifakis, R. Akolekar, D. Kappou, N. Mantas, and K. H. Nicolaides, “Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11–13 weeks in pre-eclampsia,” Prenatal Diagnosis, vol. 31, no. 2, pp. 196–201, 2011.
- S. Sifakis, R. Akolekar, D. Kappou, N. Mantas, and K. H. Nicolaides, “Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11–13 weeks in pre-eclampsia,” Journal of Human Hypertension, vol. 26, no. 4, pp. 253–258, 2012.
- S. Nanda, C. K. H. Yu, L. Giurcaneanu, R. Akolekar, and K. H. Nicolaides, “Maternal serum adiponectin at 11–13 weeks of gestation in preeclampsia,” Fetal Diagnosis and Therapy, vol. 29, no. 3, pp. 208–215, 2011.
- S. Nanda, L. C. Y. Poon, M. Muhaisen, I. C. Acosta, and K. H. Nicolaides, “Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies,” Metabolism, vol. 61, no. 5, pp. 699–705, 2012.
- A. A. Khalil, D. Tsikas, R. Akolekar, J. Jordan, and K. H. Nicolaides, “Asymmetric dimethylarginine, arfinine and homoarginine at 11–13 weeks gestation andpreeclampsia: a case-control study,” Journal of Human Hypertension. In press.
- A. Ives, C. Saunders, M. Bulsara, and J. Semmens, “Pregnancy after breast cancer: population based study,” British Medical Journal, vol. 334, no. 7586, pp. 194–196, 2007.